Month: March 2026

Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter and full year ended December 31, 2025. “Over the past year, we advanced ABS-201 from preclinical...

Expands Board as Company Accelerates Growth in Solar Recycling and Critical Metals Recovery VIRGINIA CITY, Nev., March 24, 2026 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock,” “our” and the “Company”), today announced its full year 2025 results, 2025 summary achievements, and our 2026 business outlook. “Last year marked a number of critical achievements that punctuated the turnaround from a junior mining opportunity into a validated, leading metals recovery company positioned for global growth, including final proof of our zero-landfill recycling concept from our demonstration facility, team-building, full permitting, final, first-of-its-kind engineered and tested designs, secured industrial scale facility and storage capacity and fully funded the facility and operations while also receiving direct investment from Marathon...

Fourth quarter and full year results reflect temporary planned scale back in wholesale production At year-end was back to fully planted with legacy greenhouses and the most overall acreage planted in Glass House history Full year 2026 wholesale cannabis biomass production is forecasted to be approximately 1,000,000 pounds, up approximately 50% from 2025. Year-end 2025 cash and restricted cash balance was $23.4 million, forecasting year-end 2026 cash to exceed $50 million. Conference call to be held today March 24, 2026, at 5:00 p.m. ETLONG BEACH, Calif and TORONTO, March 24, 2026 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., today reported financial...

Conference call scheduled for Tuesday, March 31, 2026 at 4:30 p.m. Eastern time DETROIT, March 24, 2026 (GLOBE NEWSWIRE) — Workhorse Group Inc. (NASDAQ: WKHS) (“Workhorse”) a North American OEM and provider of all-electric trucks, shuttles and buses, plans to conduct a conference call to discuss its fourth quarter and fiscal year 2025 results and business outlook on Tuesday, March 31, 2026, at 4:30 p.m. Eastern time. Prior to the conference call, Workhorse will issue its fourth quarter and fiscal year 2025 earnings press release. The press release may also be viewed on Workhorse’s website at ir.workhorse.com. To listen to the conference call webcast, please go to the Investor Relations section of Workhorse’s website. To listen via telephone, please call (877)-407-0789 (U.S.) or (201)-689-8562 (international). A telephonic replay...

Profitable Growth Initiatives Lead to Sequential Quarterly Improvement  Neal Cohane Appointed Interim Chief Executive Officer NORWALK, Conn., March 24, 2026 (GLOBE NEWSWIRE) — Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced financial results for the three months and 12 months ended December 31, 2025. Additionally, the Company announced that Neal Cohane has been appointed to serve as interim Chief Executive Officer and member of the board of directors, effective today. Former CEO and Board Member Cyril Wallace has stepped down. The board has begun conducting a search for a permanent CEO. Leadership Transition Cohane is a highly accomplished and seasoned retail leader. He brings decades of leadership experience across...

SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2025 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will host a corporate update conference call today, on Tuesday, March 24, 2026, at 4:30 PM ET, in which it will discuss business highlights. Call details and dial-in are provided below. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01) In parallel to advancing the regulatory discussions with the USA FDA and Japan PMDA on the potential market release of the CardiAMP System for the treatment...

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md., March 24, 2026 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter...

POMPANO BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial and Business HighlightsGenerated net revenue of $10.1 million for the fourth quarter 2025 and gross margin of 97% Completed the acquisition of the BioTissue Holdings Inc. surgical and wound assets in January 2026, significantly expanding the Company’s product portfolio, commercial footprint, and diversifying end markets into the hospital setting Integrated BioTissue’s experienced national sales force of approximately 20 direct sales representatives and managers, and more...

MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent HighlightsDelivered revenue of $20.9 million in the fourth quarter and $80.3 million for the full year 2025, an 18% and 16% increase, respectively, from the corresponding periods of 2024; Expanded the sales force to 88 quota-carrying representatives as of today under the leadership of commercial management added at midyear; Announcing promotion of Howard Langstein, MD, FACS to Chief Medical Officer, effective March 1, 2026; and Closed on a credit facility for up to $70.0 million from Perceptive Advisors (“Perceptive”). The Perceptive...